| RESEARCH ARTICLE |
|
| Year : 2014 | Volume
: 46
| Issue : 1 | Page : 46-50 |
Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice
Jeyamurugan Mookkan1, Soumita De2, Pranesha Shetty1, Nagaraj M Kulkarni1, Vijayaraj Devisingh1, Mallikarjun S Jaji1, Vinitha P Lakshmi1, Shilpee Chaudhary1, Jayanarayan Kulathingal1, Navin B Rajesh1, Shridhar Narayanan1
1 Department of Biology, Drug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Sozhanganallur, Chennai, Tamil Nadu, India
2 Department of Biology, Drug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Sozhanganallur, Chennai, Tamil Nadu; Department of Pharmacology, Rolland Institute of Pharmaceutical Sciences, Berhampur, Orissa, India
Correspondence Address:
Jeyamurugan Mookkan
Department of Biology, Drug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Sozhanganallur, Chennai, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.125166
Objectives: To evaluate the effect of vildagliptin alone and in combination with metformin or rosiglitazone on murine hepatic steatosis in diet-induced nonalcoholic fatty liver disease (NAFLD).
Materials and Methods: Male C57BL/6 mice were fed with high fat diet (60 Kcal %) and fructose (40%) in drinking water for 60 days to induce NAFLD. After the induction period, animals were divided into different groups and treated with vildagliptin (10 mg/kg), metformin (350 mg/kg), rosiglitazone (10 mg/kg), vildagliptin (10 mg/kg) + metformin (350 mg/kg), or vildagliptin (10 mg/kg) + rosiglitazone (10 mg/kg) orally for 28 days. Following parameters were measured: body weight, food intake, plasma glucose, triglyceride (TG), total cholesterol, liver function tests, and liver TG. Liver histopathology was also examined.
Results: Oral administration of vildagliptin and rosiglitazone in combination showed a significant reduction in fasting plasma glucose, hepatic steatosis, and liver TGs. While other treatments showed less or no improvement in the measured parameters.
Conclusions: These preliminary results demonstrate that administration of vildagliptin in combination with rosiglitazone could be a promising therapeutic strategy for the treatment of NAFLD.
[FULL TEXT] [PDF]*
|
